ImportantUpdates
The Board approved significant remuneration increases for key executives: MD & CEO to ₹0.64 Cr each, and an Independent Director to ₹0.24 Cr annually, pending shareholder vote.
Par Drugs and Chemicals LimitedPAR · Filed with the exchange
Directors were also empowered to lead company investment strategy, including appointing portfolio managers.
No comments yet. Be the first.